Influenza Health Article

PREVENTION AND CONTROL OF INFLUENZA

A vaccine for the prevention of influenza was developed during World War II in order to maintain military readiness. This was done in recognition of the high morbidity that could result among troops exposed to the virus. A similar inactivated vaccine is still in use, improved in both potency and lack of side effects. It is known to be 70 to 90 percent efficacious in healthy young adults as long as the vaccine viruses resemble those circulating. This necessitates updating the viruses in the vaccine each year. For this and other reasons, the vaccine must be given annually. Since vaccination programs must be sustained, the goal in most countries has been to reduce influenza mortality by vaccinating older individuals and those with chronic underlying diseases. An exception to this has been Japan, where, for a time, school-age children were vaccinated in an effort to control influenza morbidity. It has been repeatedly demonstrated that the inactivated vaccine is effective in preventing hospitalization and death in older individuals and, as such, is also cost effective. The inactivated vaccine is cost effective in healthy adults only when the attack rates are above 12 percent. A live attenuated influenza vaccine has been used in the former Soviet Union for many years, and another is in development in the United States. Because of its delivery—intranasally rather than by injection—it may prove to be particularly useful in children and younger adults.

Antiviral drugs have been available both for treatment and prophylaxis. Two of these are active only against type A viruses. A new group of drugs, acting as neuraminidase inhibitors, is active against both type A and B viruses. These drugs have been shown to have a prevention efficacy similar to vaccines. They start protecting more quickly than the vaccine, but have to be taken daily to continue protection. Therefore, vaccination will continue to be the usual means of prophylaxis. The neuraminidase inhibitors also significantly shorten the duration of illness, reducing severity and preventing complications. Influenza can be debilitating, even in the absence of complications, so that the drugs will be used for treatment during defined influenza outbreaks. They are likely also to be useful prophylactically, especially for outbreak control in nursing homes.

ARNOLD MONTO

BIBLIOGRAPHY

Belshe, R. B.; Mendelman, P. M.; Treanor, J. et al. (1998). "The Efficacy of Live Attenuated, Cold-adapted, Trivalent, Intranasal Influenza Virus Vaccine in Children." New England Journal of Medicine 149:1113–1117.

Dolin, R.; Reichman, R. C.; Madore, H. P.; Maynard, R.; Linton, P. N.; and Webber-Jones, J. (1982). "A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza A Infection." New England Journal of Medicine 307:580–584.

Douglas, R. B., Jr. (1990). "Drug Therapy: Prophylaxis and Treatment of Influenza." New England Journal of Medicine 322:443–450.

Eickhoff, T. C.; Sherman, I. L.; and Serfling, R. E. (1961). "Observations on Excess Mortality Associated with Epidemic Influenza." Journal of the American Medical Association 176:776–782.

Gubareva, L. B.; Kaiser, L.; and Hayde, F. G. (2000). "Influenza Virus Neuraminidase Inhibitors." New England Journal of Medicine 355:827–835.

Lui, K. J., and Kendal, A. P. (1987). "Impact of Influenza Epidemics on Mortality in the United States from October 1972 to May 1985." American Journal of Public Health 77:712–716.

Monto, A. S., and Arden, N. H. (1992). "Implications of Viral Resistance to Amantadine in Control of Influenza A." Clinical Infectious Diseases 15:362–367.

Monto, A. S., and Kioumehr, F. (1975). "The Tecumseh Study of Respiratory Illness. IX. Occurrence of Influenza in the Community, 1966–1971." American Journal of Epidemiology 102:553–563.

Patriarca, P. A.; Weber, J. A.; Parker, R. A. et al. (1985). "Efficacy of Influenza Vaccine in Nursing Homes: Reduction in Illness and Complications During an Influenza A (H₃N₂) Epidemic." Journal of the American Medical Association 253:1136–1139.

Sullivan, F. M.; Monto, A. S.; and Longini, I. M., Jr. (1993). "Estimates of the U.S. Health Impact of Influenza." American Journal of Public Health 83: 1712–1716.

Wilde, J. A.; McMillan, J. A.; Serwint, J.; Butta, J; O'Riordan, M. A.; and Steinhoff, M. C. (1999). "Effectiveness of Influenza Vaccine in Health Care Professionals: A Randomized Trial." Journal of the American Medical Association 281:908–913.